Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

54
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
54
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

ID93 + GLA-3M-052-LS vaccine candidate administered by heterologous routes improves BCG efficacy against TB.

Frontiers in immunology·2026
Same author

Structure and immunological activity of QS-21 variant from <i>Quillaja saponaria</i> aerial biomass.

Frontiers in immunology·2026
Same author

Mucosal vaccination in mice provides protection from diverse respiratory threats.

Science (New York, N.Y.)·2026
Same author

The ID93 + GLA-3M-052-LS vaccine candidate elicits mucosal and systemic immunogenicity and protective efficacy against <i>Mycobacterium tuberculosis</i> challenge in BCG-primed Collaborative Cross inbred mice.

bioRxiv : the preprint server for biology·2025
Same author

Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.

Cell·2025
Same author

A Thermostable nasal spray dried COVID vaccine candidate.

International journal of pharmaceutics·2025

相关实验视频

Updated: Jul 20, 2025

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection

Published on: September 1, 2023

1.9K

对于下一代辅助开发和翻译的实际考虑

William R Lykins1, Christopher B Fox1

  • 1Access to Advanced Health Institute, Seattle, WA 98102, USA.

Pharmaceutics
|July 29, 2023
PubMed
概括
此摘要是机器生成的。

由于翻译,安全性和制造方面的挑战,开发新的疫苗辅助剂需要长时间. 早期整合工具和改进的开发方法可以加速创建实用,可访问的辅助剂含有疫苗.

关键词:
辅助剂 辅助剂是一种辅助剂.设计实验的设计.这是一种配方配方.未来的前景,未来的前景.这是一种粘膜疫苗.发现自然产品的发现.管理的途径的管理路径.可持续性 可持续性 可持续性系统免疫学 免疫学疫苗研发疫苗的发展.

更多相关视频

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.7K
Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion&#45;Encapsulated Retinoic Acid System for Mucosal Vaccination
06:02

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Published on: February 23, 2024

711

相关实验视频

Last Updated: Jul 20, 2025

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection

Published on: September 1, 2023

1.9K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.7K
Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion&#45;Encapsulated Retinoic Acid System for Mucosal Vaccination
06:02

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Published on: February 23, 2024

711

科学领域:

  • 疫苗学 疫苗学 疫苗学
  • 制药发展 制药发展
  • 生物技术是生物技术.

背景情况:

  • 越来越多的学术界和行业对新型疫苗模式的疫苗辅助剂的兴趣.
  • 疫苗辅助剂开发时间表从发现到临床批准的重大延迟.
  • 关键的挑战包括跨物种转化,安全性/反应性问题以及可扩展的原材料采购.

研究的目的:

  • 审查目前疫苗辅助技术的现状.
  • 提供关于在新疫苗开发中接近和应用辅助技术的指导.
  • 确定早期整合的因素和工具,以提高临床成功.

主要方法:

  • 关于当前辅助技术和开发实践的综合文献综述.
  • 分析疫苗辅助剂翻译和制造中的常见挑战.
  • 为改善临床结果提出修改后的开发策略.

主要成果:

  • 辅助剂的开发受到翻译复杂性,安全评估和供应链问题所阻碍.
  • 目前的方法可能无法充分满足新型疫苗模式的独特需求.
  • 早期考虑特定工具和战略规划对于成功至关重要.

结论:

  • 实施修改后的开发实践和早期的战略规划可以克服当前的辅助开发障碍.
  • 这些变化旨在提高含辅助剂的疫苗产品的可访问性和实用性.
  • 建议采取积极的方法来简化从辅助剂发现到批准疫苗的过程.